Novavax Inc

NASDAQ: NVAX
$8.91
-$0.27 (-2.9%)
Closing Price on November 8, 2024

NVAX Stock Chart and Intraday Price

NVAX Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 20 FIRSTFIELD ROAD, GAITHERSBURG, MD, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 754.35M USD
Shares Outstanding 118,790,000
Novavax Inc is a biotechnology firm focused on enhancing global health by creating vaccines for serious infectious diseases. It uses innovative technologies like recombinant protein, nanoparticle technology, and its unique Matrix-M adjuvant to boost immune responses. The company has developed a COVID-19 vaccine, marketed under various names, for adults and adolescents. Additionally, Novavax is working on vaccines for influenza and a combination of influenza and COVID-19, as well as a malaria vaccine. Founded in 1987, Novavax is based in Gaithersburg, Maryland.

NVAX Articles

With the pandemic largely in the rear-view mirror, COVID-19 vaccine winner Novavax has seen shares fall. Yet, analysts have high hopes for the stock.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
Thursday's top analyst upgrades and downgrades included Bumble, Coupang, Datadog, Dish Network, DraftKings, Eli Lilly, International Flavors & Fragrances, LivePerson, Novavax, Nvidia, Qualcomm and...
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with...
Despite having positive fundamentals and being Buy rated across Wall Street, these five stocks have among the highest current short interest. They may not explode the way GameStop did in 2021, but...
Friday's top analyst upgrades and downgrades included Alphabet, Chegg, Citizens Financial, Comstock Resources, Coterra Energy, CubeSmart, Emerson Electric, Fastly, General Electric, Las Vega Sands,...
Tuesday's top analyst upgrades and downgrades included Ally Financial, Apple, Ardelyx, Block, DocuSign, D.R. Horton, Enovix, EOG Resources, Ford, Futu, Micron Technology, Novavax, PayPal, Pfizer and...
Friday morning’s analyst upgrades and downgrades included Adobe, Alcoa, Ally Financial, AppLovin, Block, Eli Lilly, Luminar Technologies, Novavax, Twilio, Wendy's, Zoom Video Communications and...
Wednesday's top analyst upgrades and downgrades included Airbnb, Amazon.com, Bank of America, Chipotle Mexican Grill, Comcast, Foot Locker, Kimberly-Clark, Meta Platforms, Novavax, Redfin, Synchrony...
Thursday's top analyst upgrades and downgrades included Caesars Entertainment, Chevron, Exact Sciences, Exxon Mobil, Gap, Ginkgo Bioworks, Home Depot, New York Mortgage Trust, Novavax, NOV and SoFi...
Wednesday's top analyst upgrades and downgrades included Bloomin' Brands, ChargePoint, Clorox, Cloudflare, Intel, Novavax, Owens Corning, Palo Alto Networks and PPL.
Stocks started off lower in Monday's premarket but were nearing a break-even start to regular trading.
Wednesday's top analyst upgrades and downgrades included DraftKings, Dollar General, Hewlett Packard Enterprise, Novavax, Rackspace, Unity Software and Weyerhaeuser.
Novavax stock jumped to close out the week after the firm announced the final efficacy numbers for its COVID-19 vaccine candidate.